GlassScriptPhysician profile
Gaby Galindo
NPI 1104254671
$4,572.74
in general payments reported to CMS, 2019-2025
28 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $625 · 2022: $695 · 2023: $1,196 · 2024: $753 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,252.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $678.26 | 2021-2025 | |
| Madrigal Pharmaceuticals | $643.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Glaxosmithkline, LLC. | $566.75 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $406.00 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $266.42 | 2021-2025 | Zepbound |
| Nestle Healthcare Nutrition INC. | $225.29 | 2022-2023 | |
| Amgen INC. | $189.01 | 2021-2025 | Evenity, Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $161.93 | 2021-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $157.74 | 2023 | Spravato |
| Pfizer INC. | $154.23 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $136.05 | 2021-2024 | Dificid, Belsomra |
| Phathom Pharmaceuticals, INC. | $124.99 | 2025 | Voquezna |
| Exact Sciences Corporation | $113.03 | 2023-2025 | Cologuard Collection Kit |
| Philips North America LLC | $100.74 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.94 | 2021-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $80.26 | 2021 | |
| Astellas Pharma US INC | $77.95 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $69.47 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $68.36 | 2022-2023 | Farxiga, Breztri |
| Seqirus USA INC | $55.87 | 2024-2025 | Fluad, Flucelvax |
| Aimmune Therapeutics, INC. | $40.14 | 2025 | Zenpep |
| Biohaven Pharmaceutical Holding Company LTD. | $28.80 | 2022 | |
| Acerus Pharmaceuticals Corporation | $28.54 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $23.49 | 2024 | Tlando |
| Ibsa Pharma INC. | $21.96 | 2021 | |
| Eisai INC. | $21.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.14 | 2022 | |
| Dexcom, INC. | $13.16 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaby Galindo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.